Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

Current Opinion in Immunology

Volumn 40, Issue , 2016, Pages vii-xiii

  Schuurman, Janine ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; DARATUMUMAB; FC RECEPTOR; FC RECEPTOR IIIA; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MOLECULAR SCAFFOLD; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL EXPANSION; CELL ISOLATION; CELLULAR IMMUNITY; CHEMICAL ENGINEERING; CONJUGATION; CYTOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; EDITORIAL; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; MEDICAL RESEARCH; MULTI TARGETING APPROACH; NONHUMAN; T LYMPHOCYTE; ANIMAL; CHEMISTRY; PROCEDURES;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY;

EID: 84964316543     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.04.001     Document Type: Editorial

References (36)

1. Reichert J.M. Antibodies to watch in 2016. MAbs 2016, 8:197-204.
2. Strohl W.R. Antibody discovery: sourcing of monoclonal antibody variable domains. Curr Drug Discov Technol 2014, 11:3-19.
3. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
4. Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Heeson S., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015, 372:724-734.
5. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461-471.
6. Labrijn A.F., Meesters J.I., de Goeij B.E., van den Bremer E.T., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013, 110:5145-5150.
7. Labrijn A.F., Meesters J.I., Priem P., de Jong R.N., van den Bremer E.T., van Kampen M.D., Gerritsen A.F., Schuurman J., Parren P.W. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014, 9:2450-2463.
8. Nunez-Prado N., Compte M., Harwood S., Alvarez-Mendez A., Lykkemark S., Sanz L., Alvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today 2015, 20:588-594.
9. Spiess C., Zhai Q., Carter P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015, 67:95-106.
10. Leger O.J., Yednock T.A., Tanner L., Horner H.C., Hines D.K., Keen S., Saldanha J., Jones S.T., Fritz L.C., Bendig M.M. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997, 8:3-16.
11. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
12. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
13. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
14. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
15. Gramer M.J., van den Bremer E.T., van Kampen M.D., Kundu A., Kopfmann P., Etter E., Stinehelfer D., Long J., Lannom T., Noordergraaf E.H., et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013, 5.
16. Stieglmaier J., Benjamin J., Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther 2015, 15:1093-1099.
17. Schuurman J., Graus Y.F., Labrijn A.F., Ruuls S., Parren P.W. Opening the door to innovation. MAbs 2014, 6:812-819.
18. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
19. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
20. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
21. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372:2006-2017.
22. Sanmamed M.F., Pastor F., Rodriguez A., Perez-Gracia J.L., Rodriguez-Ruiz M.E., Jure-Kunkel M., Melero I. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 2015, 42:640-655.
23. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, 1:32-42.
24. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
25. Furness A.J., Vargas F.A., Peggs K.S., Quezada S.A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014, 35:290-298.
26. Turnis M.E., Andrews L.P., Vignali D.A. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 2015, 45:1892-1905.
27. van de Donk N.W., Janmaat M.L., Mutis T., Lammerts van Bueren J.J., Ahmadi T., Sasser A.K., Lokhorst H.M., Parren P.W. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016, 270:95-112.
28. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
29. Ehrlich P. Ansprache bei Einweihung des Georg Speyer Hauses 1906.
30. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480.
31. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
32. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., Ramchandren R., Bartlett N.L., Cheson B.D., de Vos S., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
33. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Dieras V., Guardino E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
34. Muller P., Kreuzaler M., Khan T., Thommen D.S., Martin K., Glatz K., Savic S., Harbeck N., Nitz U., Gluz O., et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015, 7:315ra188.
35. Tzeng A., Kwan B.H., Opel C.F., Navaratna T., Wittrup K.D. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A 2015, 112:3320-3325.
36. Schuurman J., WHI Parren P. Mind the gap. Methods 2014, 65:1-4.